BRISBANE, Calif. and PARIS, May 18, 2009 (GLOBE NEWSWIRE) -- Results from a Phase II clinical trial of BiPar Sciences' -- a wholly-owned sanofi-aventis subsidiary -- lead PARP inhibitor, BSI-201, will be a featured oral plenary presentation at the 45th annual meeting of the American Society of Clinical Oncology (ASCO), Orlando, FL.
